Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.Five Prime Therapeutics shares were trading up 20.53% at $5.30 on Monday. The stock has a 52-week ...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. [3] OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. [4]
2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...
For premium support please call: 800-290-4726 more ways to reach us
Mutations are associated with numerous medical conditions including abnormal bone development (e.g. craniosynostosis syndromes) and cancer. Five Prime has a monoclonal antibody, FPA144, in early stage trials, that targets FGFR2b (a form of FGFR2), to treat gastric tumours that overexpress FGFR2b, by preventing binding of certain FGFs to FGFR2b ...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 20.80% and 29.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?